StreetInsider.com News Articles

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Fri, 05 Sep 2025 08:28:00 -0400

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.
AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.
The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.

UPPSALA, Sweden, Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a

Orexo to present clinical data for OX640 at the EAACI Congress